Illumina logo

Exploring the Power of Multiomic Solutions – Lunch & Learn at BC Cancer Research Centre

Reveal the power of the 6-base genome – introducing duet multiomics solution evoC
15 May 2024
to 15 May 2024
9:30 am
to 11:30 am
PDT
British Columbia Cancer Research Centre
, Vancouver, BC V5Z 1L3

About the event

Join biomodal and Illumina for a dynamic session led by Timothy Wilson, biomodal, Field Application Scientist.

Distinguish 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) together with all 4 canonical bases to measure multiple modes of biology from a single 5ng DNA sample, in a single experiment, with high accuracy. Identify novel multimodal biomarkers to gain transformative insights into current and future states of disease.

Come learn about new advances in Illumina sequencing, epigenomics, and other ‘omics including the introduction of 5mC and 5hmC methylation states for a comprehensive “6-base genome”. See how these new insights can change how we understand biology. Meet the experts from biomodal and Illumina to discuss how your lab can get started with these assays.

Presentation and Speakers:

Reveal the power of the 6-base genome – Introducing duet multiomicssolution evoC
Timothy Wilson, Field Application Scientist, biomodal
Epigenomics Solutions and the Broadening Power of ‘Omics
Ryan Vander Werff, Genomics Applications Scientist – Regional Lead,Ilumina
Mena Farag, Sr Manager, Genomics Specialists, Ilumina

Presenting at the event

Reveal the power of the 6-base genome for transformative insights into current and future states of disease

Timothy Wilson

Field Application Scientist

biomodal

Presentation abstract

During this Lunch & Learn, we will discuss how duet multiomics solution evoC  reveals the power of the 6-base genome in one workflow. The combinatorial genetic and epigenetic technology provides single-base-resolution sequencing data that reveals standard four-base sequencing (A, C, G, and T), and distinguishes between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC).

This added resolution will allow greater power in detecting disease associations, identifying novel biomarkers, developing disease classifiers, and monitoring the progression of disease; even with limited samples such as cell-free DNA (cfDNA).

Find the venue

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Attending from biomodal

Chad Geringer
Director of Sales and Business Development for North America

Register now

British Columbia Cancer Research Centre L&L 15May24

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.

Cambridge Epigenetix is now biomodal